GSK joins the innovation platform WIPO re:Search in its commitment to management of diseases of the developing world.

WIPO Re: Search is a collaborative project of public and private bodies sponsored by the world of intellectual property organization (WIPO, WIPO in English) with BIO Ventures for Global Health (BVGH). To offer a public database of available compounds, resources, experience and knowledge to the international community of health research, the new partnership aims to accelerate r & d of new drugs, vaccines and Diagnostics for the management of 17 neglected tropical diseases listed by the World Health Organization (who), among other dengue fever, rabies, Chagas disease, malaria or tuberculosis.

GSK will provide patent and patent applications to WIPO re:Search in the field of small molecules and formulations aimed at the development of new treatments, provide technologies to combat neglected tropical diseases, as well as anti-malarial all of your data including 13,500 compounds in the selection have demonstrated activity against malaria.

Duncan Learmouth, Vice President, Developing Countries and Market Access of GSK, has said that the new Association mark an important step in the collaboration between these groups to reduce the barriers to innovation, helping the development of new therapies and mark a difference real for the inhabitants of the countries in development. A challenge of this kind requires the industry, academia, NGOs and Governments to work in collaboration to develop new tools and approaches to ”.

This announcement adds to a series of GSK already announced and initiatives aimed at reducing the burden of all diseases of the developing world, among them:

-Tres Cantos Open Lab, where external researchers and academic centres working in the Centre of GSK in Spain dedicated to the pursuit of tratamientoiss against malariaTB and other tropical disease. So far, eight scientists from six external research organizations have collaborated on projects on campus. Ongoing projects include the research to identify and optimize compounds which can prove in human multi-fármacos, three projects other than malaria-resistant TB, including one that investigates potential GSK chemical catalog compounds, and a new approach against the parasites that cause leishmaniasis.

-A specific group of r & d focused on diseases of the developing world and tropical forgotten, which includes bacterial meningitis, Chagas disease, chlamydia, dengue, HIV/AIDS, human African trypanosomiasis, leishmaniasis, malaria, influenza fpandémica, pneumococci and tuberculosis disease.

-Investment in research into vaccines against diseases of the developing world. GSK has more than two decades of working on a vaccine against malaria. Last week announced the positive results of the phase III study of GSK, RTS, S vaccine candidate, which is being developed with the initiative for a vaccine against Malaria (MVI) PATH.

-creation of the unit of developing countries and access to the market (DMCA) in 2010 to expand access to GSK drugs of the almost 700 million people in 48 least developed countries (LDCs), of which half survives on less than a dollar per day. In these countries, GSK limits the prices of their patented drugs and vaccines to a maximum of 25% of the the rate in the developed world and reinvests 20 per cent of the benefits in projects that strengthen health infrastructure in these countries.

-donation of more than 2 billion tablets of albendazole on who to stop the transmission of lymphatic filariasis in over fifty countries. In 2011, GSK formalized a commitment of who to further extend their donation of albendazole in another 400 million tablets for the treatment of school children at risk of helminthiasis transmitted through the soil.

-consolidation of a pricing policy that helps the poorest countries pay much less than the countries of income higher by the same vaccine, with prices lower for agencies such as UNICEF, who buy a large volume of vaccines for the poorest children of the world. GSK vaccines are included in 182 countries immunization campaigns and 2010 delivered 1.4 billion doses of vaccine, that almost 1 billion were sent to countries in development

-partnerships on vaccines that help strengthen the local health infrastructure and capacity of manufacturing, including the transfer of technology. Under an agreement with the Oswaldo Cruz Foundation (Fiocruz) of Brazil for the development and manufacture of vaccines intended for urgent public health priorities in the country, GSK has established a programme of collaboration in r & d at Fiocruz for the development of a vaccine against dengue fever.

For more information about the commitment of GSK with the developing world, visit our website here

about the Consortium WIPO re:Search

GSK will become part of WIPO re:Search, an organization without precedent with representatives of the pharmaceutical industry, multilateral organizations, the academic world and NGOs. Become a member of WIPO re:Search as a user, supplier, or defender of WIPO re:Search is open to any organization who support, join or support the guiding principles of the project, which can be consulted on the website of WIPO re:Search.

The guiding principles include a commitment that intellectual property licensed via WIPO re:Search available without rights for research and development of neglected tropical diseases in any country and for the supply or sale of drugs or vaccines against tropical diseases neglected to less developed countries.

GlaxoSmithKline is one of the leading pharmaceutical and health research companies in the world. It is committed to improve the quality of human life by enabling people to do more, feel better and live longer.